4 hours Ago By Defense World Staff
D. Boral Capital reissued their buy rating on shares of OS Therapies ( NYSE:OSTX – Free Report ) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $20.
00 price objective on the stock. Separately, Maxim Group upped their target price on OS Therapies from $8.00 to $15.
00 and gave the company a “buy” rating in a research note on Thursday, January 16th. View Our Latest Stock Report on OS Therapies OS Therapies Price Performance Insider Buying and Selling In other news, major shareholder Shalom Auerbach sold 16,720 shares of OS Therapies stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $6.
74, for a total value of $112,692.80. Following the transaction, the insider now directly owns 2,531,211 shares of the company’s stock, valued at $17,060,362.
14. The trade was a 0.66 % decrease in their position.
The transaction was disclosed in a document filed with the SEC, which is available at this link . Institutional Trading of OS Therapies An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new position in OS Therapies Inc ( NYSE:OSTX – Free Report ) in the third quarter, according to the company in its most recent 13F filing with the SEC.
The institutional investor purchased 10,045 shares of the company’s stock, valued at approximately $28,000. About OS Therapies ( Get Free Report ) OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Recommended Stories Five stocks we like better than OS Therapies What Are Growth Stocks and Investing in Them ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains Overbought Stocks Explained: Should You Trade Them? Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead Low PE Growth Stocks: Unlocking Investment Opportunities Beyond Self-Driving Cars: Factory Automation Takes Center Stage Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter ..
